Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Varsha Gandhi, PhD, on Ibrutinib

May

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Varsha Gandhi, PhD, on Ibrutinib

Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status

FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer

Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma